Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
ATOVAQUONE (UNII: Y883P1Z2LT) (ATOVAQUONE - UNII:Y883P1Z2LT), PROGUANIL HYDROCHLORIDE (UNII: R71Y86M0WT) (PROGUANIL - UNII:S61K3P7B2V)
PD-Rx Pharmaceuticals, Inc.
ATOVAQUONE
ATOVAQUONE 250 mg
ORAL
PRESCRIPTION DRUG
Atovaquone and Proguanil Hydrochloride tablets are indicated for the prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported. Atovaquone and Proguanil Hydrochloride tablets are indicated for the treatment of acute, uncomplicated P. falciparum malaria. Atovaquone and proguanil hydrochloride have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance. - Atovaquone and Proguanil Hydrochloride tablets are contraindicated in individuals with known hypersensitivity reactions (e.g., anaphylaxis, erythema multiforme or Stevens-Johnson syndrome, angioedema, vasculitis) to atovaquone or proguanil hydrochloride or any component of the formulation. - Atovaquone and Proguanil Hydrochloride tablets are contraindicated for prophylaxis of P. falciparum malaria in patients with sever
Atovaquone and Proguanil Hydrochloride tablets, containing 250 mg atovaquone and 100 mg proguanil hydrochloride, are pink, film‑coated, round, biconvex tablets engraved with “GX CM3” on one side. Bottles of 190 (NDC 43063-522-68) Bottles of 280 (NDC 43063-522-69) Bottles of 375 (NDC 43063-522-73) Storage Conditions Store at 25°C (77°F). Temperature excursions are permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature).
New Drug Application Authorized Generic
ATOVAQUONE AND PROGUANIL HCL- ATOVAQUONE AND PROGUANIL HYDROCHLORIDE TABLET, FILM COATED PD-RX PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ATOVAQUONE AND PROGUANIL HYDROCHLORIDE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ATOVAQUONE AND PROGUANIL HYDROCHLORIDE. ATOVAQUONE AND PROGUANIL HYDROCHLORIDE TABLETS INITIAL U.S. APPROVAL: 2000 INDICATIONS AND USAGE Atovaquone and Proguanil Hydrochloride tablets are an antimalarial indicated for: prophylaxis of _Plasmodium falciparum_ malaria, including in areas where chloroquine resistance has been reported. ( 1.1) treatment of acute, uncomplicated _P. falciparum_ malaria. ( 1.2) DOSAGE AND ADMINISTRATION Atovaquone and Proguanil Hydrochloride tablets should be taken with food or a milky drink. Prophylaxis (2.1): Start prophylaxis 1 or 2 days before entering a malaria‑endemic area and continue daily during the stay and for 7 days after return. Adults: One adult strength tablet per day. Treatment (2.2): Adults: Four adult strength tablets as a single daily dose for 3 days. Renal Impairment (2.3): Do not use for prophylaxis of malaria in patients with severe renal impairment. Use with caution for treatment of malaria in patients with severe renal impairment. DOSAGE FORMS AND STRENGTHS Tablets (adult strength): 250 mg atovaquone and 100 mg proguanil hydrochloride. ( 3) CONTRAINDICATIONS Known serious hypersensitivity reactions to atovaquone or proguanil hydrochloride or any component of the formulation. ( 4) Prophylaxis of _P. falciparum_ malaria in patients with severe renal impairment (creatinine clearance <30 _ _mL/min). ( 4) WARNINGS AND PRECAUTIONS Atovaquone absorption may be reduced in patients with diarrhea or vomiting. If used in patients who are vomiting, parasitemia should be closely monitored and the use of an antiemetic considered. In patients with severe or persistent diarrhea or vomiting, alternative antimalarial therapy may be required. ( 5.1) In mi Citiți documentul complet